TRUCKEE Study gives hope to neovascular AMD patients
Speaking at the 2022 American Society of Retina Specialists, Dr. Carl Danzig reported recent TRUCKEE study results demonstrating real-world safety and efficacy. The presentation detailed how treatment with Faricimab (Vabysmo, Roche) in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments. The investigators also showed that the subretinal and intraretinal fluid decreased in patients over the course of treatment with Faricimab.
